Lilly Asian Ventures Looking For Chinese Companies To Invest In
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Lilly Asian Ventures will focus on directly investing into individual companies under its second phase of investment in China, the firm announced Nov.7 in Shanghai
You may also be interested in...
BeiGene CEO John Oyler On Investing In Biotech In China: An Interview With PharmAsia News (Part 1 Of 2)
BeiGene CEO John Oyler discusses what is missing in China’s venture capital environment if it truly wants to foster innovation. Based in Beijing, BeiGene’s lead product entered the clinic in 2013.
From Biosimilars To Corporate Venture: China's Top Biotech Takes Another Step
3SBio Inc.'s success with a biosimilar of erythropoietin Epogen has spurred the Chinese company to form a RMB 250 million venture fund with China Medical City, an up-and-coming science and technology park that is backed by China's national government.
From Biosimilars To Corporate Venture: China's Top Biotech Takes Another Step
3SBio Inc.'s success with a biosimilar of erythropoietin Epogen has spurred the Chinese company to form a RMB 250 million venture fund with China Medical City, an up-and-coming science and technology park that is backed by China's national government.